MedTrace Logo

Rosuvastatin in African Americans With Cerebrovascular Disease

NCT01975194 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-11-05

No results posted yet for this study

Summary

This study will assess the rate at which rosuvastatin will achieve LDL targets in African American patients with previous history of stroke or TIA.

Conditions

  • Stroke
  • Transient Ischemic Attack

Interventions

DRUG

Rosuvastatin

Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks

Sponsors & Collaborators

  • Wayne State University

    lead OTHER

Principal Investigators

  • Seemant Chaturvedi, MD · Wayne State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01975194 on ClinicalTrials.gov